[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.180.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1965

Divergent Effects in the Treatment of Hyperlipemia

Author Affiliations

BROOKLYN

From the Department of Medicine, State University of New York Downstate Medical Center and the Kings County Hospital, Brooklyn. Instructor, Department of Medicine (Dr. Slowe); Associate Professor, Department of Medicine (Dr. Carter); and Assistant Professor, Department of Medicine (Dr. Feldman).

Arch Intern Med. 1965;116(4):523-530. doi:10.1001/archinte.1965.03870040037009
Abstract

THORP AND WARING demonstrated that clofibrate (Atromid S) lowered levels of serum and liver cholesterol in rats.1 Other studies suggested that a mixture of androsterone and clofibrate (Atromid) potentiated the lipid-lowering effect.2 The successful use of this mixture to decrease serum lipid concentration in patients with coronary sclerosis by Oliver in 19623 prompted the present study of the effects of clofibrate alone or with androsterone in patients with frank disorders of lipid metabolism. In the course of these investigations, published reports suggested that clofibrate alone was responsible for the lipid-lowering action of the mixture and that addition of androsterone produced no enhancement.4-8

Materials and Methods  The patients (Table 1) ranged in age from 10 to 72 years. They included four men, three women with hyperlipemia, a boy with idiopathic hyperlipemia, and a boy with glycogen-storage disease (glucose-6-phosphatase deficient). In five of seven families studied familial incidence of hyperlipemia was demonstrated.

First Page Preview View Large
First page PDF preview
First page PDF preview
×